ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0151

Five-Month Impact of Tozinameran (BNT162b2) Vaccine on Kidney Transplant and Dialysis Patients: Serology and Clinical Outcomes

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Dranitzki Elhalel, Michal, Hadassah Hebrew University Medical Center, Department of Nephrology and Hypertension, Jerusalem, Israel
  • Tzukert, Keren, Hadassah Hebrew University Medical Center, Department of Nephrology and Hypertension, Jerusalem, Israel
  • Mor yosef levi, Irit, Hadassah Hebrew University Medical Center, Department of Nephrology and Hypertension, Jerusalem, Israel
  • Burstain, Ido, Hadassah Hebrew University Medical Center, Department of Nephrology and Hypertension, Jerusalem, Israel
  • Pri Chen, Hadass, Hadassah Hebrew University Medical Center, Department of Nephrology and Hypertension, Jerusalem, Israel
  • Oster, Yonatan, Hadassah Hebrew University Medical Center, Department of Clinical Microbiology and Infectious Diseases, Jerusalem, Israel
  • Wolf, Dana G., Hadassah Hebrew University Medical Center, Department of Clinical Microbiology and Infectious Diseases, Jerusalem, Israel
  • Ben-Dov, Iddo Z., Hadassah Hebrew University Medical Center, Department of Nephrology and Hypertension, Jerusalem, Israel
Background

Dialysis-treated (DT) and kidney transplant (TX) patients face higher morbidly and mortality risks than the general population during COVID-19 pandemic. Determining humoral response and associated COVID-19 morbidity after vaccination will guide risk assessment and changes in vaccination policy in this vulnerable population.

Methods

Prospective cohort study up to 5 months follow-up after Tozinameran or SARS-CoV-2 infection. Primary outcomes: qualitative and quantitative anti S1/S2 antibody (ABs) and disease rates during follow up.
Anti-SARS-2 IgG ABs were quantified using LIAISON SARS-CoV-2 S1/S2 IgG (DiaSorin) immunoassay in serum of TX, DT and treating team at our hospital. Demographics and clinical data were collected from participants files.

Results

174 DT patients (40% women, age 65±15 years) 253 TX patients (33%, 53±14 years) and 71 control participants (65%, 44±14 years) were recruited. 3 months or more after vaccination we detected anti S1/S2 ABs in 81% of DT (95%CI, 72-90%), 43% of TX (95%CI, 29-57%) and 100% of controls. After COVID-19 respective rates were 94% (95%CI, 83-100%), 75% (95%CI, 60-90%) and 100%. Quantitative titers were in line with qualitative ones. Predictors of negative serology were older age, diabetes, cancer history, lower lymphocyte count and lower vitamin D. Peritoneal dialysis predicted higher titers compared to hemodialysis. In TX, hypertension and higher levels of immnosupression predicated lower titers. Vaccination was associated with fewer subsequent COVID-19 infections (HR=0.23, 95% CI 0.05-0.99, p<0.05). Higher antibody titers associated with fewer events, HR 0.41/unit increase in log10titer (p<0.05).

Conclusion

Patients with ESRD, particularly TX, mounted delayed and diminished antibody response to vaccination, and lesser response was associated with more infections. Thus, measures to protect non-responsive patients are urgently required.